LAS VEGAS, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today the U.S. sales launch of ImmunAG™, the market’s first non-cannabis cannabidiol (CBD) product derived from the hops plant. The time-released tablet will be unveiled at the Marijuana Business Conference and Expo (MJBizCon) in Las Vegas and available for purchase through Isodiol’s website.
“The release of ImmunAG is a monumental milestone for Isodiol, as it marks the industry’s first foray into non-cannabis CBD products,” said Marcos Agramont, CEO of Isodiol. “This launch is a continuation of our company strategy to provide a diverse range of products as we strive to increase shareholder value by creating entirely new market segments.”
Using proprietary extraction and purification methodologies, Isodiol is able to maintain the bioactivity (or a substances’ effectiveness on a target) of the molecule at a level much greater than anything currently derived from the cannabis plant. The ImmunAG tablet does not dissolve in the stomach but rather dissolves in the lower intestine, creating greater bioactivity.
“Cannabis is accepted by less than 10% of the world, while the hops plant is accepted universally,” said Agramont. “This significant expansion of the global marketplace, paired with our ability to manufacture and distribute the product world-wide, gives us access to practically every country and avails this product and subsequent products to the global marketplace.”
The Company will be exhibiting all its product offerings at Booth #714 and #4699 of MJBizCon from Nov. 15-17 in Las Vegas at the Marijuana Business Conference and Expo.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
North 6th Agency
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.